KPV

What KPV does

KPV is a three-amino-acid fragment of alpha-MSH. Gut-inflammation findings come from cells and animals, including mice given KPV by mouth. No published human dosing, benefit or safety study was found. People report oral and injected use, but neither has an established human dose. Product identity and long-term risks remain uncertain.

• In mouse studies, it reduced gut inflammation, including in mice given it by mouth. (animal)
• A few users report gut-symptom relief or less bloating; another reported no clear benefit. (Reported by users)
• In an animal study, it sped healing of wounds on the eye surface in rabbits. (animal)

Uses in the sources

• People report using it for gut symptoms and inflammation. The supporting colitis experiments are in mice, not human trials. (Reported by users) (source)
• Topical wound and skin uses are discussed, but FDA found no human effectiveness studies. Rabbit eye-wound results do not support home eye drops. (Reported by users) (source)

KPV dosage

Typical reported dose: 150–300 mcg a day by mouth

• Oral pills, 150-300 mcg: 150-300 mcg per day reported; 600 mcg/day was only planned. daily; precise timing not reported, by mouth. Reported by users, occasional report. Studied in: Adults describing gut symptoms on a forum. (source)
• Reported 500 mcg daily: 500 mcg under the skin once daily. once daily, under the skin. Reported by users, occasional report. Studied in: One adult reporting gut-inflammation self-use. (source)
• Reported two-week steps: 250 mcg daily for 2 weeks., then 500 mcg daily for 2 weeks., then 1,000 mcg daily for 2 weeks. daily, as reported in the same discussion, under the skin. Reported by users, rare report. Studied in: One forum user describing use for MCAS-like symptoms. (source)
• Reported twice daily with BPC-157: 250 mcg KPV per injection, twice daily; also 250 mcg BPC-157 each time. twice daily, morning and evening, under the skin. Reported by users, rare report. Studied in: A secondhand report about an adult with SIBO symptoms. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix KPV

Comes as: Oral pills or capsules reported in forums, Lyophilised powder in vials reported in forums, Experimental creams, gels and delivery particles.

Mixed with: Forums describe bacteriostatic water. No human study validates a diluent for injectable KPV..

Common vial sizes: 10 mg. Common water amounts: mL.

• Syringe units measure volume, not peptide mass. A clear solution does not establish identity, sterility or absence of endotoxin.
• FDA reports storage claims for different KPV forms, but these do not establish a sterile multidose-vial expiry.
• A laboratory HPLC study found breakdown under acid, alkali and peroxide stress; it did not validate a home-mixed injection shelf life.

Before mixing: No approved storage label. Storage depends on the chemical form and formulation; FDA notes gaps in stability and quality data.

After mixing: No validated human-use shelf life or beyond-use date. Do not borrow a 28-day rule from the diluent.

KPV side effects and risks

Reported side effects

• Human adverse-effect rates are unknown: No human safety trial or formal rate estimate. No reports in FDA searches through December 3, 2025 does not prove safety., moderate. Review new symptoms promptly; absence of reports is not evidence of safety. (source)
• Fatigue or symptom flares reported online: Unverified reports; no denominator or confirmed cause., moderate. Stop and seek assessment for worsening symptoms. (source)
• Possible serious allergic reaction: FDA describes immune reaction risk; KPV specific incidence is unknown., serious. Breathing trouble, throat swelling or fainting needs emergency care. (source)

Stop and get help if

• Trouble breathing, throat swelling or collapse: Stop exposure and get emergency help immediately.
• Fever with a spreading hot, painful injection site: Seek urgent care for possible infection.
• New severe or worsening symptoms after use: Stop and obtain medical assessment; do not assume a normal detox reaction.
• Severe belly pain, heavy or nonstop rectal bleeding, or vomiting blood: Get emergency medical help now.
• Bloody diarrhea with fever or a fast heartbeat: Obtain urgent same-day assessment; a severe bowel flare may need hospital care.

Who should avoid it

• pregnant: Precautionary block. No human pregnancy safety studies were found.
• breastfeeding: Precautionary block. Milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block. Reproductive and developmental safety is unstudied.
• under18: No pediatric dose or safety evidence; adult-only reference.
• melanomaOrAtypicalMoles: Melanoma safety is unstudied. KPV lacks alpha-MSH pigment activity in preclinical work; melanotan risks cannot simply be assigned to KPV.
• kidneyDisease: No human clearance or dose-adjustment data in kidney disease.
• liverDisease: No human clearance or dose-adjustment data in liver disease.
• immunosuppressed: Immune effects and infection risk with immunosuppressive treatment have not been tested in people.
• other: Avoid re-exposure after a suspected serious allergy to KPV or any ingredient.
• testedAthlete: S0 prohibits unapproved pharmacological substances at all times. Verify status with the relevant anti-doping body.

Interactions

• Systemic immunosuppressants: Precaution only. No human interaction data establish how KPV combines with immune-suppressing medicines.

Product quality risks

• FDA found inconsistent KPV naming and incomplete quality data, including missing microbiological tests.
• Unregulated peptides may have the wrong ingredient or amount, microbes, endotoxins, solvents or other contaminants.
• No independent market survey measuring contamination or underdosing of KPV products was found.

What to expect

No human intervention study identified. Six key animal studies are listed; human cell or biopsy work does not establish a human dose.

Key studies

• PepT1 and mouse colitis: KPV entered cells via PepT1 and reduced inflammation in two mouse colitis models. (source)
• Two mouse colitis models: KPV reduced gut inflammation even when MC1R signaling was impaired. (source)
• Rabbit corneal wounds: KPV sped corneal wound closure in rabbits; this is not evidence for human eye use. (source)
• Colitis-associated tumors in mice: KPV reduced tumor formation in wild-type mice, not PepT1-knockout mice. (source)
• Targeted oral KPV particles: A special gut-targeting formulation improved delivery and reduced mouse colitis. (source)
• Inflammation-targeted proKPV: A modified KPV delivery system improved tissue uptake in mice. (source)

KPV FAQ

• Is KPV FDA-approved? No. KPV acetate: limited to oral, topical forms. The October 30, 2026 Federal Register describes a nonbinding draft interim HHS 503A enforcement policy, with public comment invited. It is conditional on eligible state-licensed pharmacies, federal facilities or licensed physicians, a patient-specific prescription, a single active ingredient, specified identity and route, qualified manufacturing, lot testing, reporting and labeling conditions. It is not FDA drug approval, a final 503A listing or general authorization to supply research products.
• How do people take it? By mouth, daily; precise timing not reported. Source: reported by users, not an established dose.
• What's the difference between KPV and BPC-157? KPV: an alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial. BPC-157: an experimental repair peptide with mostly animal evidence and a few small human reports. Why people pair them: reported for gut symptoms and recovery; no human combination trial found.
• Can I take it with BPC-157? Reported for gut symptoms and recovery; no human combination trial found. Combined effects, safety and attribution of benefits are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Inferred from S0 for unapproved pharmacological substances. Neither peptide is named individually; athletes should verify with their anti-doping body.
• How long does a mixed vial last? No validated human-use shelf life or beyond-use date. Do not borrow a 28-day rule from the diluent.